CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 82.12% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money

Trade Quince Therapeuticks Inc - QNCX CFD

1.3682
2.15%
  • Summary
  • Historical Data
Trading сonditions
Spread 0.0336
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.023512 %
Charges from full value of position ($-4.47)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.023512%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.00129 %
Charges from full value of position ($0.25)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.00129%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5.00%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 1.3982
Open 1.4082
1-Year Change 7.75%
Day's Range 1.3582 - 1.4182
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Feb 21, 2025 1.3682 -0.0400 -2.84% 1.4082 1.4182 1.3582
Feb 20, 2025 1.3982 0.0100 0.72% 1.3882 1.4382 1.3882
Feb 19, 2025 1.4082 -0.0400 -2.76% 1.4482 1.5182 1.3982
Feb 18, 2025 1.3782 -0.0300 -2.13% 1.4082 1.4582 1.3782
Feb 14, 2025 1.3882 0.0100 0.73% 1.3782 1.4182 1.3682
Feb 13, 2025 1.3782 -0.0300 -2.13% 1.4082 1.4582 1.3582
Feb 12, 2025 1.3882 0.0200 1.46% 1.3682 1.3982 1.3682
Feb 11, 2025 1.3782 -0.0200 -1.43% 1.3982 1.4082 1.3782
Feb 10, 2025 1.4182 -0.0300 -2.07% 1.4482 1.4782 1.3482
Feb 7, 2025 1.4282 -0.0400 -2.72% 1.4682 1.5882 1.4282
Feb 6, 2025 1.5182 -0.1500 -8.99% 1.6682 1.6682 1.5182
Feb 5, 2025 1.6282 0.1600 10.90% 1.4682 1.6782 1.4682
Feb 4, 2025 1.5182 -0.1300 -7.89% 1.6482 1.6482 1.5082
Feb 3, 2025 1.5682 0.0600 3.98% 1.5082 1.5782 1.4982
Jan 31, 2025 1.5882 0.0000 0.00% 1.5882 1.5982 1.5482
Jan 30, 2025 1.5582 -0.0500 -3.11% 1.6082 1.6082 1.5582
Jan 29, 2025 1.6082 0.0100 0.63% 1.5982 1.6082 1.5682
Jan 28, 2025 1.5382 -0.1500 -8.89% 1.6882 1.6882 1.5282
Jan 27, 2025 1.6682 0.1300 8.45% 1.5382 1.6882 1.5282
Jan 24, 2025 1.5682 0.0000 0.00% 1.5682 1.6082 1.5582

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 3:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Cortexyme Inc. Company profile

About Cortexyme Inc

Cortexyme, Inc. is a clinical stage biopharmaceutical company that is focused on providing disease-modifying therapeutics to treat Alzheimer's and other degenerative diseases. The Company provides 3CLpro inhibitor, COR803 product, is a lead compound for treatment of coronavirus infections. The Company’s products pipeline includes drug candidates for the treatment of central nervous system (CNS) disorders including Alzheimer’s disease; for the treatment of oncology applications including the prevention of oral squamous cell carcinoma, and for the treatment of underserved and chronic conditions such as periodontitis. The Company’s COR388 is for the treatment of Alzheimer’s disease and Parkinson's disease. The Company's COR588 is in Phase I clinical trial and targeting to use in the treatment of periodontal disease and other P. gingivalis-related indications. The Company is also developing COR588, is a second-generation brain penetrant lysine gingipain inhibitor.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Cortexyme Inc revenues was not reported. Net loss increased 17% to $89.9M. Higher net loss reflects Stock-based Compensation in R&D increase from $7M to $15.1M (expense), Stock-based Compensation in GA increase of 99% to $14.8M (expense), General and administrative - Balancing increase of 45% to $14.7M (expense).

Industry: Biotechnology & Medical Research (NEC)

601 Gateway Boulevard, Suite 1250
SOUTH SAN FRANCISCO
CALIFORNIA 94080
US

People also watch

ETH/USD

2,779.27 Price
+5.290% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 1.75

Gold

2,936.56 Price
-0.110% 1D Chg, %
Long position overnight fee -0.0149%
Short position overnight fee 0.0067%
Overnight fee time 22:00 (UTC)
Spread 0.30

US100

21,594.40 Price
-2.120% 1D Chg, %
Long position overnight fee -0.0235%
Short position overnight fee 0.0013%
Overnight fee time 22:00 (UTC)
Spread 7.0

BTC/USD

96,674.75 Price
+1.390% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 50.00

Still looking for a broker you can trust?

Join the 690,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading